Skip to content

Study · Non-randomized trial · n = 90 · 2017

15 results

Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study.

Caron PJ, Petersenn S, Houchard A, Sert C, Bevan JS

Clinical endocrinology27 Dec 2016Cited by 23 (Europe PMC)

PMID27874199 (opens in a new tab)DOI10.1111/cen.13285 (opens in a new tab)PepBankPUB-27874199
Source linkPubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In the overall acromegaly population, HbA1c did not significantly change during lanreotide treatment by week 48.

    In plain wordsHbA1c did not significantly change from baseline during lanreotide treatment in the overall population.

    Peptide
    Lanreotide
    Outcome
    No significant changeHbA1c in overall population
    Study

    n = 90

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    In the overall population, in patients without diabetes, or in patients with/without hormonal control, HbA1c did not significantly change by week 48.
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    Treatment-naïve adults with pituitary macroadenoma, mean growth hormone >1 μg/l and elevated insulin-like growth factor-1 levels (n = 90).
  2. 02HumanNon-randomized trialEfficacy outcome

    In the overall acromegaly population, mean fasting plasma glucose did not significantly change from baseline during lanreotide treatment by week 48.

    In plain wordsMean fasting glucose did not significantly change from baseline during lanreotide treatment in the overall population.

    Peptide
    Lanreotide
    Outcome
    No significant changeFasting plasma glucose in overall population
    Study

    n = 90

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean FPG levels showed no significant change by week 48 in all populations.
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    Treatment-naïve adults with pituitary macroadenoma, mean growth hormone >1 μg/l and elevated insulin-like growth factor-1 levels (n = 90).
  3. 03HumanNon-randomized trialEfficacy outcome

    In acromegaly patients with diabetes, HbA1c decreased during lanreotide treatment (week 48 change -1·44%, CI -2·52 to -0·36).

    In plain wordsIn acromegaly patients with diabetes, HbA1c decreased during lanreotide treatment compared with baseline.

    Peptide
    Lanreotide
    Outcome
    DecreaseHbA1c in diabetes subgroup
    Study

    n = 24

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Measurements

    mean HbA1c change from baseline
    −1.44%
    diabetes subgroup, week 48; 95% CI -2.52 to -0.36
    95% CI of mean change
    −2.52 to −0.36%
    diabetes subgroup, week 48

    Source sentences

    Summary
    In patients with diabetes (n = 24), HbA1c showed a clinically relevant decrease during treatment [mean change from baseline to week 48, -1·44% (95% CI: -2·52, -0·36)].
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    Treatment-naïve adults with pituitary macroadenoma, mean growth hormone >1 μg/l and elevated insulin-like growth factor-1 levels (n = 90).
  4. 04HumanNon-randomized trialEfficacy outcome

    In acromegaly patients with diabetes, mean fasting plasma glucose did not significantly change from baseline during lanreotide treatment by week 48.

    In plain wordsIn patients with diabetes, fasting glucose did not significantly change from baseline during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    No significant changeFasting plasma glucose in patients with diabetes
    Study

    n = 24

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean FPG levels showed no significant change by week 48 in all populations.
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    In patients with diabetes (n = 24), HbA1c showed a clinically relevant decrease during treatment [mean change from baseline to week 48, -1·44% (95% CI: -2·52, -0·36)].
  5. 05HumanNon-randomized trialEfficacy outcome

    In acromegaly patients without diabetes, HbA1c did not significantly change during lanreotide treatment by week 48.

    In plain wordsHbA1c did not significantly change from baseline during lanreotide treatment in patients without diabetes.

    Peptide
    Lanreotide
    Outcome
    No significant changeHbA1c in patients without diabetes
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    In the overall population, in patients without diabetes, or in patients with/without hormonal control, HbA1c did not significantly change by week 48.
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    Treatment-naïve adults with pituitary macroadenoma, mean growth hormone >1 μg/l and elevated insulin-like growth factor-1 levels (n = 90).
  6. 06HumanNon-randomized trialEfficacy outcome

    In acromegaly patients with hormonal control, HbA1c did not significantly change during lanreotide treatment by week 48.

    In plain wordsHbA1c did not significantly change from baseline during lanreotide treatment in patients with hormonal control.

    Peptide
    Lanreotide
    Outcome
    No significant changeHbA1c in patients with hormonal control
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    In the overall population, in patients without diabetes, or in patients with/without hormonal control, HbA1c did not significantly change by week 48.
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    Treatment-naïve adults with pituitary macroadenoma, mean growth hormone >1 μg/l and elevated insulin-like growth factor-1 levels (n = 90).
  7. 07HumanNon-randomized trialEfficacy outcome

    In acromegaly patients without hormonal control, HbA1c did not significantly change during lanreotide treatment by week 48.

    In plain wordsHbA1c did not significantly change from baseline during lanreotide treatment in patients without hormonal control.

    Peptide
    Lanreotide
    Outcome
    No significant changeHbA1c in patients without hormonal control
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    In the overall population, in patients without diabetes, or in patients with/without hormonal control, HbA1c did not significantly change by week 48.
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    Treatment-naïve adults with pituitary macroadenoma, mean growth hormone >1 μg/l and elevated insulin-like growth factor-1 levels (n = 90).
  8. 08HumanNon-randomized trialEfficacy outcome

    During lanreotide treatment, some acromegaly patients in all populations had increases or decreases in glycemic parameters.

    In plain wordsSome patients had increases or decreases in blood sugar measures during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    MixedIndividual glycemic parameter changes
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Individually, increases and decreases in glycaemic parameters affected some patients in all populations.
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    Treatment-naïve adults with pituitary macroadenoma, mean growth hormone >1 μg/l and elevated insulin-like growth factor-1 levels (n = 90).
  9. 09HumanNon-randomized trialEfficacy outcome

    During lanreotide treatment, glycemic status remained stable in 70% overall, 50% with diabetes, and 76% without diabetes.

    In plain wordsCompared with baseline, glycemic status remained stable in most patients during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    Not applicableStable composite glycemic status
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Measurements

    Stable composite glycemic status
    70%
    overall population
    Stable composite glycemic status
    50%
    patients with diabetes
    Stable composite glycemic status
    76%
    patients without diabetes

    Source sentences

    Summary
    Glycaemic status as a composite measure of HbA1c and FPG (classification as normal, mild or diabetic) was stable from baseline to study end in most patients (overall, 70%; patients with diabetes, 50%; patients without diabetes, 76%)
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    Treatment-naïve adults with pituitary macroadenoma, mean growth hormone >1 μg/l and elevated insulin-like growth factor-1 levels (n = 90).
  10. 10HumanNon-randomized trialSafety outcome

    During lanreotide treatment, glycemic status worsened in nine (15%) patients, including seven (50%) with diabetes at baseline.

    In plain wordsCompared with baseline, glycemic status worsened in some patients during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    Not applicableWorsening composite glycemic status
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Measurements

    Patients with worsened composite glycemic status
    9 patients
    overall population, by week 48
    Patients with worsened composite glycemic status
    15%
    overall population, by week 48
    Worsened patients with diabetes at baseline
    7 patients
    reported as seven (50%)
    Worsened patients with diabetes at baseline
    50%
    patients with diabetes at baseline

    Source sentences

    Summary
    but worsened by week 48 in nine (15%) patients [seven (50%) with diabetes at baseline]
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    Treatment-naïve adults with pituitary macroadenoma, mean growth hormone >1 μg/l and elevated insulin-like growth factor-1 levels (n = 90).
  11. 11HumanNon-randomized trialEfficacy outcome

    During lanreotide treatment, glycemic status improved in nine (15%) patients, none with diabetes.

    In plain wordsCompared with baseline, glycemic status improved in some patients during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    Not applicableImproving composite glycemic status
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Measurements

    Patients with improved composite glycemic status
    9 patients
    overall population, by week 48
    Patients with improved composite glycemic status
    15%
    overall population, by week 48

    Source sentences

    Summary
    and improved in nine (15%) patients (none with diabetes).
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    Treatment-naïve adults with pituitary macroadenoma, mean growth hormone >1 μg/l and elevated insulin-like growth factor-1 levels (n = 90).
  12. 12HumanNon-randomized trialEfficacy outcome

    In acromegaly patients receiving lanreotide, lipid profile changes were not considered clinically meaningful.

    In plain wordsLipid profile changes during lanreotide treatment were not considered clinically meaningful compared with baseline.

    Peptide
    Lanreotide
    Outcome
    Not applicableLipid profile changes
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Changes in lipid profiles were not considered clinically meaningful.
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    Treatment-naïve adults with pituitary macroadenoma, mean growth hormone >1 μg/l and elevated insulin-like growth factor-1 levels (n = 90).
  13. 13HumanNon-randomized trialEfficacy outcome

    In acromegaly patients without diabetes, mean fasting plasma glucose did not significantly change from baseline during lanreotide treatment by week 48.

    In plain wordsIn patients without diabetes, fasting glucose did not significantly change from baseline during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    No significant changeFasting plasma glucose in patients without diabetes
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean FPG levels showed no significant change by week 48 in all populations.
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    A priori and post hoc metabolic profile data are reported for the overall population, patients with/without diabetes and patients achieving/not achieving hormonal control.
  14. 14HumanNon-randomized trialEfficacy outcome

    In acromegaly patients with hormonal control, mean fasting plasma glucose did not significantly change from baseline during lanreotide treatment by week 48.

    In plain wordsIn patients with hormonal control, fasting glucose did not significantly change from baseline during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    No significant changeFasting plasma glucose in patients with hormonal control
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean FPG levels showed no significant change by week 48 in all populations.
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    A priori and post hoc metabolic profile data are reported for the overall population, patients with/without diabetes and patients achieving/not achieving hormonal control.
  15. 15HumanNon-randomized trialEfficacy outcome

    In acromegaly patients without hormonal control, mean fasting plasma glucose did not significantly change from baseline during lanreotide treatment by week 48.

    In plain wordsIn patients without hormonal control, fasting glucose did not significantly change from baseline during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    No significant changeFasting plasma glucose in patients without hormonal control
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 mg every 4 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean FPG levels showed no significant change by week 48 in all populations.
    2 context sentences
    Summary · context
    PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks.
    Summary · context
    A priori and post hoc metabolic profile data are reported for the overall population, patients with/without diabetes and patients achieving/not achieving hormonal control.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.